Adverse reactions during acute and chronic class I antiarrhythmic therapy

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The short- and long-term outcomes of patients treated with class I antiarrhythmic drugs were studied. A total of 968 patients who began class I antiarrhythmic therapy in our hospital were followed up for a mean of 13 ± 8 months. Discontinuation rates were similar for the entire group of patients during short-term therapy (52%) and long-term therapy (50%). During short-term therapy, 28% of patients stopped treatment because of side effects, and 21% of patients discontinued treatment because of ineffectiveness. Discontinuation rates during short-term therapy were significantly lower with encainide, flecainide, and procainamide than with the other agents (disopyramide, mexiletine, qunidine gluconate, quinidine sulfate, and tocainide) (P <0.05). However, encainide, flecainide, and procainamide were associated with a higher incidence of side effects necessitating discontinuation in the long-term study. Side effects during long-term therapy accounted for 27% of discontinuations, while loss of efficacy accounted for only 6%. Discontinuation rates were significantly lower with mexiletine, quinidine sulfate, and tocainide than with the other agents during long-term therapy (P <0.05). The discontinuation rate with quinidine gluconate was significantly less than that with quinidine sulfate. All antiarrhythmic agents possess a substantial potential for toxicity. Short-term response and tolerance to class I antiarrhythmics do not predict the ultimate response to therapy. Thus patients receiving class I antiarrhythmic therapy must be monitored for the duration of treatment.

Original languageEnglish
Pages (from-to)730-738
Number of pages9
JournalCurrent Therapeutic Research - Clinical and Experimental
Volume51
Issue number5
StatePublished - 1992

Fingerprint

Quinidine
Encainide
Tocainide
Therapeutics
Mexiletine
Flecainide
Procainamide
Disopyramide
Anti-Arrhythmia Agents
Incidence

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{a4a3416a529d40e4bd8c0a69942a199a,
title = "Adverse reactions during acute and chronic class I antiarrhythmic therapy",
abstract = "The short- and long-term outcomes of patients treated with class I antiarrhythmic drugs were studied. A total of 968 patients who began class I antiarrhythmic therapy in our hospital were followed up for a mean of 13 ± 8 months. Discontinuation rates were similar for the entire group of patients during short-term therapy (52{\%}) and long-term therapy (50{\%}). During short-term therapy, 28{\%} of patients stopped treatment because of side effects, and 21{\%} of patients discontinued treatment because of ineffectiveness. Discontinuation rates during short-term therapy were significantly lower with encainide, flecainide, and procainamide than with the other agents (disopyramide, mexiletine, qunidine gluconate, quinidine sulfate, and tocainide) (P <0.05). However, encainide, flecainide, and procainamide were associated with a higher incidence of side effects necessitating discontinuation in the long-term study. Side effects during long-term therapy accounted for 27{\%} of discontinuations, while loss of efficacy accounted for only 6{\%}. Discontinuation rates were significantly lower with mexiletine, quinidine sulfate, and tocainide than with the other agents during long-term therapy (P <0.05). The discontinuation rate with quinidine gluconate was significantly less than that with quinidine sulfate. All antiarrhythmic agents possess a substantial potential for toxicity. Short-term response and tolerance to class I antiarrhythmics do not predict the ultimate response to therapy. Thus patients receiving class I antiarrhythmic therapy must be monitored for the duration of treatment.",
author = "Hilleman, {Daniel E.} and Mohiuddin, {Syed M.} and Gannon, {J. M.}",
year = "1992",
language = "English",
volume = "51",
pages = "730--738",
journal = "Current Therapeutic Research",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "5",

}

TY - JOUR

T1 - Adverse reactions during acute and chronic class I antiarrhythmic therapy

AU - Hilleman, Daniel E.

AU - Mohiuddin, Syed M.

AU - Gannon, J. M.

PY - 1992

Y1 - 1992

N2 - The short- and long-term outcomes of patients treated with class I antiarrhythmic drugs were studied. A total of 968 patients who began class I antiarrhythmic therapy in our hospital were followed up for a mean of 13 ± 8 months. Discontinuation rates were similar for the entire group of patients during short-term therapy (52%) and long-term therapy (50%). During short-term therapy, 28% of patients stopped treatment because of side effects, and 21% of patients discontinued treatment because of ineffectiveness. Discontinuation rates during short-term therapy were significantly lower with encainide, flecainide, and procainamide than with the other agents (disopyramide, mexiletine, qunidine gluconate, quinidine sulfate, and tocainide) (P <0.05). However, encainide, flecainide, and procainamide were associated with a higher incidence of side effects necessitating discontinuation in the long-term study. Side effects during long-term therapy accounted for 27% of discontinuations, while loss of efficacy accounted for only 6%. Discontinuation rates were significantly lower with mexiletine, quinidine sulfate, and tocainide than with the other agents during long-term therapy (P <0.05). The discontinuation rate with quinidine gluconate was significantly less than that with quinidine sulfate. All antiarrhythmic agents possess a substantial potential for toxicity. Short-term response and tolerance to class I antiarrhythmics do not predict the ultimate response to therapy. Thus patients receiving class I antiarrhythmic therapy must be monitored for the duration of treatment.

AB - The short- and long-term outcomes of patients treated with class I antiarrhythmic drugs were studied. A total of 968 patients who began class I antiarrhythmic therapy in our hospital were followed up for a mean of 13 ± 8 months. Discontinuation rates were similar for the entire group of patients during short-term therapy (52%) and long-term therapy (50%). During short-term therapy, 28% of patients stopped treatment because of side effects, and 21% of patients discontinued treatment because of ineffectiveness. Discontinuation rates during short-term therapy were significantly lower with encainide, flecainide, and procainamide than with the other agents (disopyramide, mexiletine, qunidine gluconate, quinidine sulfate, and tocainide) (P <0.05). However, encainide, flecainide, and procainamide were associated with a higher incidence of side effects necessitating discontinuation in the long-term study. Side effects during long-term therapy accounted for 27% of discontinuations, while loss of efficacy accounted for only 6%. Discontinuation rates were significantly lower with mexiletine, quinidine sulfate, and tocainide than with the other agents during long-term therapy (P <0.05). The discontinuation rate with quinidine gluconate was significantly less than that with quinidine sulfate. All antiarrhythmic agents possess a substantial potential for toxicity. Short-term response and tolerance to class I antiarrhythmics do not predict the ultimate response to therapy. Thus patients receiving class I antiarrhythmic therapy must be monitored for the duration of treatment.

UR - http://www.scopus.com/inward/record.url?scp=0026600141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026600141&partnerID=8YFLogxK

M3 - Article

VL - 51

SP - 730

EP - 738

JO - Current Therapeutic Research

JF - Current Therapeutic Research

SN - 0011-393X

IS - 5

ER -